Sponsors / RLMD
RLMD

Relmada Therapeutics, Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
6Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDDNCT03051256RLMDPhase 2Completed2019-07-30Actual
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)NCT04688164RLMDPhase 3Completed2022-11-01Actual
Safety of REL-1017 for Major Depressive DisorderNCT04855760RLMDPhase 3Completed2023-07-27Actual
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)NCT05081167RLMDPhase 3Completed2022-09-13Actual
A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBCNCT06663137RLMDPhase 2Recruiting2027-11Estimated
A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder CancerNCT07464145RLMDPhase 3Not yet recruiting2029-12Estimated

Latest recorded trial changes